MYD88 and lymphoma: We also observed that HJ901 (10 or 25 mg/kg) treatment suppressed lymphoma growth in a mouse DLBCL xenogeneic tumor model with TMD8 cells harboring the MyD88 L265P mutation, rather than U2932 cells with wild-type MyD88 (Figures 4B–D).